Equities Analysts Issue Forecasts for TVTX FY2025 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Wedbush decreased their FY2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research note issued to investors on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.74) per share for the year, down from their prior forecast of ($0.69). Wedbush currently has a "Outperform" rating and a $30.00 price target on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics' Q4 2025 earnings at ($0.08) EPS and Q1 2026 earnings at ($0.05) EPS.

Several other analysts also recently weighed in on the company. Canaccord Genuity Group lifted their target price on Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Travere Therapeutics in a research note on Tuesday, July 1st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Travere Therapeutics in a research note on Wednesday, April 23rd. Citigroup cut their price target on shares of Travere Therapeutics from $35.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, June 11th. Finally, Guggenheim reaffirmed a "buy" rating and set a $47.00 price objective on shares of Travere Therapeutics in a report on Monday, April 14th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.14.

Travere Therapeutics Stock Down 0.9%

Shares of NASDAQ TVTX traded down $0.15 during midday trading on Thursday, reaching $16.51. 1,367,155 shares of the company's stock were exchanged, compared to its average volume of 1,611,732. The company has a debt-to-equity ratio of 9.46, a quick ratio of 2.03 and a current ratio of 2.05. The stock has a market capitalization of $1.47 billion, a PE ratio of -5.88 and a beta of 0.72. Travere Therapeutics has a 52-week low of $7.93 and a 52-week high of $25.29. The business's fifty day moving average price is $15.95 and its two-hundred day moving average price is $18.06.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,179.73% and a negative net margin of 82.88%. The firm had revenue of $81.73 million during the quarter, compared to the consensus estimate of $77.44 million. During the same period last year, the business posted ($1.76) EPS. Travere Therapeutics's quarterly revenue was up 83.3% on a year-over-year basis.

Insider Activity at Travere Therapeutics

In related news, insider Peter Heerma sold 1,771 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,279.55. Following the completion of the transaction, the insider owned 128,215 shares of the company's stock, valued at $2,698,925.75. This represents a 1.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Eric M. Dube sold 18,924 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $398,350.20. Following the completion of the transaction, the chief executive officer directly owned 419,173 shares of the company's stock, valued at approximately $8,823,591.65. The trade was a 4.32% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,294 shares of company stock worth $485,123. Insiders own 4.19% of the company's stock.

Institutional Investors Weigh In On Travere Therapeutics

Several large investors have recently modified their holdings of TVTX. Driehaus Capital Management LLC raised its stake in Travere Therapeutics by 608.1% in the fourth quarter. Driehaus Capital Management LLC now owns 2,217,975 shares of the company's stock valued at $38,637,000 after purchasing an additional 1,904,733 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Travere Therapeutics by 479.9% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,184,898 shares of the company's stock valued at $39,153,000 after buying an additional 1,808,098 shares during the period. Armistice Capital LLC boosted its position in Travere Therapeutics by 20.6% during the 1st quarter. Armistice Capital LLC now owns 8,872,000 shares of the company's stock valued at $158,986,000 after buying an additional 1,514,000 shares during the period. BNP Paribas Financial Markets purchased a new stake in Travere Therapeutics during the 4th quarter valued at $21,075,000. Finally, Nuveen LLC bought a new position in Travere Therapeutics in the 1st quarter worth $21,569,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.